The systemic nature of mustard lung: Comparison with COPD patients

Open access

Abstract

Sulphur mustard (SM) is a powerful blister-causing alkylating chemical warfare agent used by Iraqi forces against Iran. One of the known complications of mustard gas inhalation is mustard lung which is discussed as a phenotype of chronic obstructive pulmonary disease (COPD). In this complication, there are clinical symptoms close to COPD with common etiologies, such as in smokers. Based on information gradually obtained by conducting the studies on mustard lung patients, systemic symptoms along with pulmonary disorders have attracted the attention of researchers. Changes in serum levels of inflammatory markers, such as C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), nuclear factor κB (NF-κB), matrix metalloproteinases (MMPs), interleukin (IL), chemokines, selectins, immunoglobulins, and signs of imbalance in oxidant-antioxidant system at serum level, present the systemic changes in these patients. In addition to these, reports of extra-pulmonary complications, such as osteoporosis and cardiovascular disease are also presented. In this study, the chance of developing the systemic nature of this lung disease have been followed on using the comparative study of changes in the mentioned markers in mustard lung and COPD patients at stable phases and the mechanisms of pathogenesis and phenomena, such as airway remodeling in these patients.

Adamson IY, Bowden DH. (1974). The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 77: 185–197.

Agin K. (2004). Comparison of prevalence of osteoporosis in patients with asthma following chemical injury in patients with asthma Sulfur-mustard non chemical victims. Mil Res J 4: 419–422.

Agusti A, Soriano JB. (2008). COPD as a systemic disease. COPD: Journal of Chronic Obstructive Pulmonary Disease 5: 133–138.

Aldonyte R, Eriksson S, Piitulainen E, Wallmark A, Janciauskiene S. (2004). Analysis of systemic biomarkers in COPD patients. Copd 1: 155–164.

Anderson GP. (2006). COPD, asthma and C-reactive protein. Eur Respir J 27: 874–876.

Attaran D, Lari SM, Khajehdaluee M, Ayatollahi H, Towhidi M, Asnaashari A, Marallu HG, Mazloomi M, Balali-Mood M. (2009). Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complication of sulfur mustard poisoning and its correlation with severity of airway diseases. Hum Exp Toxicol 28: 739–745.

Attaran D, Lari SM, Towhidi M, Marallu HG, Ayatollahi H, Khajehdaluee M, Ghanei M, Basiri R. (2010). Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 5: 335–340.

Balali-Mood M, Afshari R, Zojaji R, Kahrom H, Kamrani M, Attaran D, Mousavi SR, Zare GA. (2011). Delayed toxic effects of sulfur mustard on respiratory tract of Iranian veterans. Hum Exp Toxicol 30(9): 1141–1149.

Barnes PJ, Celli BR. (2009). Systemic manifestations and comorbidities of COPD. Eur Respir J 33: 1165–1185.

Barnes TC, Anderson ME, Moots RJ. (2011). The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011: 721608.

Batra S, Balamayooran G, Sahoo MK. (2011). Nuclear factor-kappaB: a key regulator in health and disease of lungs. Arch Immunol Ther Exp (Warsz) 59: 335–351.

Bayat N, Aslani J. (2010). Comparing the bone mineral density in chemical injures and non-chemical asmatic patients. Trauma Monthly 2011: 105–110.

Biskobing DM. (2002). COPD and osteoporosis. Chest 121: 609–620.

Blackwell TS, Christman JW. (1997). The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 17: 3–9.

Calderon TM, Berman JW. (2005). Overview and history of chemokines and their receptors. Current Topics in Membranes 55: 1–47.

Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, investigators T. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775–789.

Carter JD, Patel S, Sultan FL, Thompson ZJ, Margaux H, Sterrett A, Carney G, Murphy N, Huang Y, Valeriano J, Vasey FB. (2008). The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med 102: 1165–1172.

Comhair SA, Bhathena PR, Dweik RA, Kavuru M, Erzurum SC. (2000). Rapid loss of superoxide dismutase activity during antigen-induced asthmatic response. Lancet 355: 624.

Comhair SA, Erzurum SC. (2002). Antioxidant responses to oxidant-mediated lung diseases. Am J Physiol Lung Cell Mol Physiol 283: L246–255.

Dahl M, Nordestgaard BG. (2009). Markers of early disease and prognosis in COPD. Int J Chron Obstruct Pulmon Dis 4: 157–167.

Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. (2007). C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 175: 250–255.

Dayhimi I, Bahar K, Eliasy H. (1988). The effect of sulfur mustard gas (SMG) on the immune system. In: The First International Medical Congress on Chemical Warfare Agents in Iran Mashhad, Iran: Mashhad University of Medical Sciences.

de Moraes MR, da Costa AC, Correa Kde S, Junqueira-Kipnis AP, Rabahi MF. (2014). Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD. Int J Chron Obstruct Pulmon Dis 9: 735–743.

Denk A, Wirth T, Baumann B. (2000). NF-kappaB transcription factors: critical regulators of hematopoiesis and neuronal survival. Cytokine Growth Factor Rev 11: 303–320.

Egeblad M, Werb Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174.

Ekstrand-Hammarstrom B, Wigenstam E, Bucht A. (2011). Inhalation of alkylating mustard causes long-term T cell-dependent inflammation in airways and growth of connective tissue. Toxicology 280: 88–97.

Emad A, Rezaian GR. (1999). Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. Chest 115: 1346–1351.

Evison D, Hinsley D, Rice P. (2002). Regular review: chemical weapons. BMJ: British Medical Journal 324: 332.

Fakhraddin F, Reza SA, Yahya D, Akbar KZA, Mahdi C. (1999). Does Sulfur Mustard (HD) have an accelerating effect on CABG in HD-exposed people? Is it a link? Medical Science and Technology 48: RA11–RA13.

Firoozabadi MD, Shahriary A, Rahmani H. (2017). Mustard lung anesthesia; general anesthesia for patients with chronic obstructive pulmonary disease due to sulphur mustard exposure. Minerva Pneumol 56: 254–257.

Fooladi AAI, Nourani MR, Yazdani S. (2012). Lung and Systemic Inflammation in COPD: INTECH Open Access Publisher.

Foronjy RF, Okada Y, Cole R, D’Armiento J. (2003). Progressive adult-onset emphysema in transgenic mice expressing human MMP-1 in the lung. Am J Physiol Lung Cell Mol Physiol 284: L727–737.

Fukuda Y, Ishizaki M, Kudoh S, Kitaichi M, Yamanaka N. (1998). Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest 78: 687–698.

Geddes EL, Reid WD, Crowe J, O’Brien K, Brooks D. (2005). Inspiratory muscle training in adults with chronic obstructive pulmonary disease: a systematic review. Respir Med 99: 1440–1458.

Ghanei M, Adibi I, Farhat F, Aslani J. (2008). Late respiratory effects of sulfur mustard: how is the early symptoms severity involved? Chronic respiratory disease 5: 95–100.

Ghanei M, Harandi AA. (2007). Long term consequences from exposure to sulfur mustard: a review. Inhal Toxicol 19: 451–456.

Ghasemi H, Ghazanfari T, Babaei M, Soroush MR, Yaraee R, Ghassemi-Broumand M, Javadi MA, Foroutan A, Mahdavi MR, Shams J, Pourfarzam S, Moaiedmohseni S, Nadoushan MR, Owlia P, Panahi Y, Hassan ZM, Faghihzadeh S. (2008). Long-term ocular complications of sulfur mustard in the civilian victims of Sardasht, Iran. Cutan Ocul Toxicol 27: 317–326.

Ghasemi H, Ghazanfari T, Yaraee R, Ghassemi-Broumand M, Soroush MR, Pourfarzam S, Masdari Z, Faghihzadeh S, Babaei M, Javadi MA. (2009). Evaluation of relationship between the serum levels of inflammatory mediators and ocular injuries induced by sulfur mustard: Sardasht-Iran Cohort Study. Int Immunopharmacol 9(13–14): 1494–1498.

Ghasemi H, Mostafaie A, Yaraee R, Hassan ZM, Rezaei A, Mahmoudi M, Faghihzadeh S, Soroush MR, Ardestani SK, Babaei M, Jalali-Nadoushan M, Khamesipour A, Ghassemi-Broumand M, Ghazanfari T. (2013). Association of serum immunoglobulins levels and eye injuries in sulfur mustard exposed: Sardasht-Iran Cohort Study. Int Immunopharmacol 17: 944–951.

Ghazanfari T, Mostafaie A, Yaraee R, Pourfarzam S, Faghihzadeh S, Rezaei A, Mahmoudi M, Vaez-Mahdavi MR, Moaiedmohseni S, Soroush MR, Naghizadeh MM, Faghihzadeh E, Hassan ZM. (2013). Are serum levels of immunoglobulin classes and IgG subclasses involved in delayed pulmonary complications induced by sulfur mustard? Sardasht-Iran Cohort Study. Int Immunopharmacol 17: 936–943.

Ghazanfari T, Yaraee R, Kariminia A, Ebtekar M, Faghihzadeh S, Vaez-Mahdavi MR, Rezaei A, Vojgani M, Soroush MR, Kermani-Jalilvand A. (2009). Alterations in the serum levels of chemokines 20years after sulfur mustard exposure: Sardasht-Iran Cohort Study. Int Immunopharmacol 9(13–14): 1471–6.

Ghotbi L, Hassan Z. (2002). The immunostatus of natural killer cells in people exposed to sulfur mustard. Int Immunopharmacol 2: 981–985.

Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. (2009). Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 34: 209–218.

Groot Kormelink T, Pardo A, Knipping K, Buendia-Roldan I, Garcia-de-Alba C, Blokhuis BR, Selman M, Redegeld FA. (2011). Immunoglobulin free light chains are increased in hypersensitivity pneumonitis and idiopathic pulmonary fibrosis. PLoS One 6: e25392.

Hammad DR, Elgazzar AG, Essawy TS, El Sameie SAA. (2015). Evaluation of serum interleukin-1 beta as an inflammatory marker in COPD patients. Egyptian Journal of Chest Diseases and Tuberculosis 64: 347–352.

Hassan ZM, Ebtekar M, Ghanei M, Taghikhani M, Noori Daloii MR, Ghazanfari T. (2006). Immunobiological consequences of sulfur mustard contamination. Iran J Allergy Asthma Immunol 5: 101–108.

Hayden MS, Ghosh S. (2008). Shared principles in NF-kappaB signaling. Cell 132: 344–362.

Hefazi M, Attaran D, Mahmoudi M, Balali-Mood M. (2005). Late respiratory complications of mustard gas poisoning in Iranian veterans. Inhal Toxicol 17: 587–592.

Heidari A, Sheikhi MA, Rahmani H. (2016). Inflammatory status of Non-Smoker Sulphur Mustard exposed Patient with Cancer candidate for Coronary artery bypass grafting Surgery. Int J Pharm Res Allied Sci 5: 196–198.

Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. (2009). Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 103(8): 1231–1238.

Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA. (2006). Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174(8): 867–874.

Husain K, Dube SN, Sugendran K, Singh R, Das Gupta S, Somani SM. (1996). Effect of topically applied sulphur mustard on antioxidant enzymes in blood cells and body tissues of rats. J Appl Toxicol 16: 245–248.

Chauhan S, Gupta MK, Goyal A, Dasgupta DJ. (1990). Alterations in immunoglobulin & complement levels in chronic obstructive pulmonary disease. Indian J Med Res 92: 241–245.

Chung KF. (2005). Inflammatory mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy 4: 619–625.

Imani S, Panahi Y, Salimian J, Fu J, Ghanei M. (2015). Epigenetic: A missing paradigm in cellular and molecular pathways of sulfur mustard lung: a prospective and comparative study. Iran J Basic Med Sci 18: 723–736.

Imanifooladi A A, Yazdani S, Nourani MR. (2010). The role of nuclear factor-kappaB in inflammatory lung disease. Inflamm Allergy Drug Targets 9(3): 197–205.

Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS. (1999). Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 116: 1616–1624.

Irwin CR, Myrillas TT, Traynor P, Leadbetter N, Cawston TE. (2002). The role of soluble interleukin (IL)-6 receptor in mediating the effects of IL-6 on matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 expression by gingival fibroblasts. J Periodontol 73: 741–747.

Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, Takahashi H, Fukuchi Y, Ouchi Y. (2000). Neither IL-1 β, IL-1 receptor antagonist, nor TNF-α polymorphisms are associated with susceptibility to COPD. Respir Med 94: 847–851.

Jorgensen NR, Schwarz P. (2008). Osteoporosis in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 14: 122–127.

Karadag F, Karul AB, Cildag O, Yilmaz M, Ozcan H. (2008a). Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. Lung 186: 403–409.

Karadag F, Kirdar S, Karul AB, Ceylan E. (2008b). The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 19(2): 104–108.

Karbasi-Afshar R, Shahmari A, Madadi M, Poursaleh Z, Saburi A. (2013). Coronary angiography findings in lung injured patients with sulfur mustard compared to a control group. Ann Card Anaesth 16: 188–192.

Kelley WN, Harris ED, Ruddy S, Sledge CB. (1997). Textbook of rheumatology: WB Saunders Philadelphia.

Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. (2003). Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 45(11): 1136–1143.

Kiani A, Mostafaie A, Shirazi FH, Ghazanfari T. (2013). Serum profiles of matrix metalloproteinases and their tissue inhibitors in long-term pulmonary complication induced by sulfur mustard: Sardasht-Iran Cohort Study (SICS). Int Immunopharmacol 17(3): 964–967.

Kim H, Liu X, Kohyama T, Kobayashi T, Conner H, Abe S, Fang Q, Wen F-Q, Rennard SI. (2004). Cigarette smoke stimulates MMP-1 production by human lung fibroblasts through the ERK1/2 pathway. COPD 1(1): 13–23.

Kony S, Zureik M, Driss F, Neukirch C, Leynaert B, Neukirch F. (2004). Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. Thorax 59: 892–896.

Kopff M, Zakrzews ka I, Strzelczyk M, Klem J, Dubiecki W. (1993). Superoxide dismutase and catalase activity in psoriatic patients treated topically with ointment containing 2-chloroethyl-3-chloropropyl sulfide. Pol J Pharmacol 46(5): 439–444.

Kraus VB, Stabler TV, Luta G, Renner JB, Dragomir AD, Jordan JM. (2007). Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarthritis Cartilage 15(8): 966–971.

Krumbhaar EB, Krumbhaar HD. (1919). The Blood and Bone Marrow in Yelloe Cross Gas (Mustard Gas) Poisoning: Changes produced in the Bone Marrow of Fatal Cases. J Med Res 40: 497–508.

Lahousse L, Loth DW, Joos GF, Hofman A, Leufkens HG, Brusselle GG, Stricker BH. (2013). Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther 26: 212–217.

Lai Y, Liu X, Zeng Y, Zhang Y, Shen Y, Liu Y. (2012). Interleukin-8 induces the endothelial cell migration through the Rac1/RhoA-p38MAPK pathway. Cell 51: 38MAPK.

Langen RC, Korn S H, Wouters EF. (2003). ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med 35: 226–235.

Lari SM, Attaran D, Towhidi M. (2012). COPD Due to Sulfur Mustard (Mustard Lung): INTECH Open Access Publisher.

Laskin DL, Sunil VR, Laumbach RJ, Kipen HM. (2007). Inflammatory cytokines and lung toxicity. In: Cytokines in Human Health, pp 83–112: Springer.

Lee KY, Ho SC, Chan YF, Wang CH, Huang CD, Liu WT, Lin SM, Lo YL, Chang YL, Kuo LW, Kuo HP. (2012). Reduced nuclear factor-kappaB repressing factor: a link toward systemic inflammation in COPD. Eur Respir J 40: 863–873.

Lehmann W, Edgar CM, Wang K, Cho TJ, Barnes GL, Kakar S, Graves DT, Rueger JM, Gerstenfeld LC, Einhorn TA. (2005). Tumor necrosis factor alpha (TNF-alpha) coordinately regulates the expression of specific matrix metalloproteinases (MMPS) and angiogenic factors during fracture healing. Bone 36: 300–310.

Levitt JM, Lodhi IJ, Nguyen PK, Ngo V, Clift R, Hinshaw DB, Sweeney JF. (2003). Low-dose sulfur mustard primes oxidative function and induces apoptosis in human polymorphonuclear leukocytes. Int Immunopharmacol 3: 747–756.

Ley K. (2003). The role of selectins in inflammation and disease. Trends Mol Med 9: 263–268.

Littner MR. (2011). In the clinic. Chronic obstructive pulmonary disease. Ann Intern Med 154: ITC4-1-ITC4-15; quiz ITC14-16.

MacNee W. (2005). Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 50–60.

Mahmoudi M, Hefazi M, Rastin M, Balali-Mood M. (2005). Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans. Int Immunopharmacol 5: 1479–1485.

Man SF, Xing L, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Zhang X, Vessey R, Walker TG, Celli BR, Sin DD. (2008). Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Eur Respir J 32: 1451–1457.

Miedema I, Feskens EJ, Heederik D, Kromhout D. (1993). Dietary determinants of long-term incidence of chronic nonspecific lung diseases. The Zutphen Study. Am J Epidemiol 138: 37–45.

Mirbagher Ajorpaz N, Rezaei M. (2009). The Effects of pulmonary rehabilitation techniques on the clinical status of patients with moderate severity chronic obstructive pulmonary diseases (COPD) at University Hospitals of Isfahan in 2006–7. ZUMS Journal 17: 1–12.

Mishra NC, Rir-sima-ah J, Grotendorst GR, Langley RJ, Singh SP, Gundavarapu S, Weber WM, Pena-Philippides JC, Duncan MR, Sopori ML. (2012). Inhalation of sulfur mustard causes long-term T cell-dependent inflammation: possible role of Th17 cells in chronic lung pathology. Int Immunopharmacol 13: 101–108.

Moermans C, Heinen V, Nguyen M, Henket M, Sele J, Manise M, Corhay JL, Louis R. (2011). Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. Cytokine 56: 298–304.

Moin A, Ghazanfari T, Davoudi SM, Emadi N, Panahi Y, Hassan ZM, Soroush MR, Khateri S, Amini R, Naghizadeh MM. (2009). Long-term skin findings of sulfur mustard exposure on the civilians of Sardasht, Iran. Toxin Reviews 28: 24–29.

Montano M, Sansores RH, Becerril C, Cisneros J, Gonzalez-Avila G, Sommer B, Ochoa L, Herrera I, Ramirez-Venegas A, Ramos C. (2014). FEV1 inversely correlates with metalloproteinases 1, 7, 9 and CRP in COPD by biomass smoke exposure. Respir Res 15: 74.

Naghii MR. (2002). Sulfur mustard intoxication, oxidative stress, and antioxidants. Mil Med 167: 573–575.

Nussbaumer-Ochsner Y, Rabe KF. (2011). Systemic manifestations of COPD. Chest 139: 165–173.

O’Keeffe S, Gzel A, Drury R, Cullina M, Greally J, Finnegan P. (1991). Immunoglobulin G subclasses and spirometry in patients with chronic obstructive pulmonary disease. Eur Respir J 4: 932–936.

Paromov V, Suntres Z, Smith M, Stone WL. (2007). Sulfur mustard toxicity following dermal exposure: role of oxidative stress, and antioxidant therapy. J Burns Wounds 7: e7.

Parvizpour F, Ghazanfari T, Salimi H, Faghihzadeh S, Yaraee R, Sharifnia Z, Soroosh MR, Naghizadeh MM. (2011). NFκB gene expression survey in peripheral blood cell of sardasht warfare agent victims 20 years after exposure to sulfur mustard. Tebe-E-Janbaz 3(12): 38–47.

Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B. (2007). Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 62: 595–601.

Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. (2006). C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 61: 23–28.

Pourfarzam S, Ghazanfari T, Merasizadeh J, Ghanei M, Azimi G, Araghizadeh H, Foroutan A, Shams J, Ghasemi H, Yaraee R. (2009a). Long-term pulmonary complications in sulfur mustard victims of Sardasht, Iran. Toxin Reviews 28: 8–13.

Pourfarzam S, Ghazanfari T, Yaraee R, Ghasemi H, Hassan ZM, Faghihzadeh S, Ardestani SK, Kariminia A, Fallahi F, Soroush MR, Merasizadeh J, Mahlojirad M, Naghizadeh MM, Ghanei M. (2009b). Serum levels of IL-8 and IL-6 in the long term pulmonary complications induced by sulfur mustard: Sardasht-Iran Cohort Study. Int Immunopharmacol 9: 1482–1488.

Pourfarzam S, Yaraee R, Hassan ZM, Yarmohammadi ME, Faghihzadeh S, Soroush MR, Fallahi F, Ardestani SK, Ebtekar M, Moaiedmohseni S, Naghizadeh MM, Ghasemi H, Shams J, Ghazanfari T. (2013). Chemokines, MMP-9 and PMN elastase in spontaneous sputum of sulfur mustard exposed civilians: Sardasht-Iran Cohort Study. Int Immunopharmacol 17: 958–963.

Procianoy RS, Silveira RC. (2004). The role of sample collection timing on interleukin-6 levels in early-onset neonatal sepsis. J Pediatr (Rio J) 80: 407–410.

Rahmani H, Javadi I, Shirali S. (2016). Respiratory complications due to sulfur mustard exposure. Int J Curr Res Acad Rev 4(6): 143–149.

Rahmani H, Javadi I, Shirali S. (2017). Evaluation of serum levels of interleukin-6 and C-reactive protein in mustard lung patients and its relationship with pulmonary complications. Minerva Pneumologica 56: 84–89.

Reid MB, Lannergren J, Westerblad H. (2002). Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med 166: 479–484.

Rezaian GR, Emad A, Ghayumi MA, Rezaian S, Zare N. (2008). Exercise intolerance and chronotropic impairment-The long-term cardiovascular sequelae of mustard gas exposure: A paired-comparative study. Environ Toxicol Pharmacol 26: 212–215.

Riahi-Zanjani B, Balali-Mood M, Mousavi SR, Karimi G, Sadeghi M, Shirmast E, Mahmoudi M. (2014). Serum cytokine profiles of Khorasan veterans 23 years after sulfur mustard exposure. Cytokine 70: 161–164.

Rohani A, Akbari V, Moghadam FT. (2010). A case control study of cardiovascular health in chemical war disabled Iranian victims. Indian J Crit Care Med 14: 109–112.

Rutten FH, Moons K G, Cramer MJ, Grobbee DE, Zuithoff NP, Lammers JW, Hoes AW. (2005). Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 331: 1379.

Sabourin CL, Danne MM, Buxton KL, Casillas RP, Schlager JJ. (2002). Cytokine, chemokine, and matrix metalloproteinase response after sulfur mustard injury to weanling pig skin. J Biochem Mol Toxicol 16: 263–272.

Samaha HMS, Elsaid AR, NasrEldin E. (2015). Total serum IgE level in COPD patients. Egypt J Chest Dis Tuberc 64(3): 573–577.

Sapey E, Ahmad A, Bayley D, Newbold P, Snell N, Rugman P, Stockley RA. (2009). Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol 29(4): 508–516.

Shahriary A, Mehrani H, Ghanei M, Parvin S. (2015). Comparative proteome analysis of peripheral neutrophils from sulfur mustard-exposed and COPD patients. J Immunotoxicol 12: 132–139.

Shahriary A, Panahi Y, Shirali S, Rahmani H. (2017). Relationship of serum levels of interleukin 6, interleukin 8, and C-reactive protein with forced expiratory volume in first second in patients with mustard lung and chronic obstructive pulmonary diseases: systematic review and meta-analysis. Postepy Dermatol Alergol. 34(3): 192–198.

Shahriary A, Rahmani H. (2017). Need to study of systemic markers changes in acute phase of respiratory complication due to sulfur mustard. Toxin Reviews 36(3): 261–263.

Sheikhi MA, Rahmani H. (2016). Inflammatory statuses of non-smoker mustard lung patient candidate for coronary artery bypass grafting surgery. Int J Pharm Res Allied Sci 5: 194–195.

Sheu B. (2008). Levels of neutrophils stimulation and matrix Metalloprotease in plasma of individuals with elevated blood pressure and acute/long-term exercise: ProQuest.

Shohrati M, Amini-Harandi A, Najafian B, Saburi A, Ghanei M. (2014a). The role of serum level of interleukin-6 i n severity of pulmonary complications of sulfur mustard injuries. Iran J Med Sci 39: 382–386.

Shohrati M, Ghanei M, Shamspour N, Jafari M, Khasmakhi MNA. (2009). Extra cellular Superoxide Dismutase activity in lung injuries due to Sulfur Mustard. J Qazvin Uni Med Sci 12: 5–11.

Shohrati M, Haji Hosseini R, Esfandiari MA, Najafian N, Najafian B, Golbedagh A. (2014b). Serum matrix metalloproteinase levels in patients exposed to sulfur mustard. Iran Red Crescent Med J 16: e15129.

Shrivastava AK, Singh HV, Raizada A, Singh SK. (2015). C-reactive protein, inflammation and coronary heart disease. The Egyptian Heart Journal 67(2): 89–97.

Schols AM. (2002). Pulmonary cachexia. Int J Cardiol 85: 101–110.

Schumacher A, Liebers U, John M, Gerl V, Meyer M, Witt C, Wolff G. (2005). P-selectin glycoprotein ligand-1 (PSG L-1) is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease. Clin Exp Immunol 142(2): 370–376.

Schunemann HJ, Dorn J, Grant BJ, Winkelstein W, Trevisan M. (2000). Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. CHEST Journal 118: 656–664.

Schwartz J, Weiss ST. (1990). Dietary factors and their relation to respiratory symptoms the second national health and nutrition examination survey. Am J Epidemiol 132(1): 67–76.

Schwartz J, Weiss ST. (1994). Relationship between dietary vitamin C intake and pulmonary function in the First National Health and Nutrition Examination Survey (NHANES I). Am J Clin Nutr 59(1): 110–114.

Siebenlist U, Brown K, Claudio E. (2005). Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immuno l 5: 435–445.

Sies H, Stahl W. (1995). Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Am J Clin Nutr 62(6 Suppl): 1315S–1321S.

Sin DD, Man SF. (2005). Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol 83: 8–13.

Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M. (2003). Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 58: 752–756.

Strachan DP, Cox BD, Erzinclioglu SW, Walters DE, Whichelow MJ. (1991). Ventilatory function and winter fresh fruit consumption in a random sample of British adults. Thorax 46: 624–629.

Strieter RM, Kunkel SL, Bone RC. (1993). Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 21: S447–463.

Tabak C, Feskens EJ, Heederik D, Kromhout D, Menotti A, Blackburn HW. (1998). Fruit and fish consumption: a possible explanation for population differences in COPD mortality (The Seven Countries Study). Eur J Clin Nutr 52: 819–825.

Tsuruta J, Sugisaki K, Dannenberg AM, Jr., Yoshimura T, Abe Y, Mounts P. (1996). The cytokines NAP-1 (IL-8), MCP-1, IL-1 beta, and GRO in rabbit inflammatory skin lesions produced by the chemical irritant sulfur mustard. Inflammation 20: 293–318.

Vaillant P, Menard O, Vignaud JM, Martinet N, Martinet Y. (1996). The role of cytokines in human lung fibrosis. Monaldi Arch Chest Dis 51: 145–152.

Visse R, Nagase H. (2003). Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827–839.

Voll-Aanerud M, Eagan TM, Wentzel-Larsen T, Gulsvik A, Bakke PS. (2008). Respiratory symptoms, COPD severity, and health related quality of life in a general population sample. Respir Med 102: 399–406.

Weinberger B, Laskin JD, Sunil VR, Sinko PJ, Heck DE, Laskin DL. (2011). Sulfur mustard-induced pulmonary injury: therapeutic approaches to mitigating toxicity. Pulm Pharmacol Ther 24: 92–99.

Wouters EF, Creutzberg EC, Schols AM. (2002). Systemic effects in COPD. CHEST Journal 121: 127S–130S.

Wright JG, Christman JW. (2003). The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2: 211–219.

Wu S, Chen P, Jiang X, Liu Z. (2005). C-reactive protein level and the correlation between lung function and CRP levels in patients with chronic obstructive pulmonary diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban 30(4): 444–446. [in Chinese]

Yaraee R, Ghazanfari T, Ebtekar M, Ardestani SK, Rezaei A, Kariminia A, Faghihzadeh S, Mostafaie A, Vaez-Mahdavi MR, Mahmoudi M. (2009a). Alterations in serum levels of inflammatory cytokines (TNF, IL-1alpha, IL-1beta and IL-1Ra) 20years after sulfur mustard exposure: Sardasht-Iran cohort study. Int Immunopharmacol 9(13–14): 1466–1470.

Yaraee R, Ghazanfari T, Faghihzadeh S, Mostafaie A, Soroush MR, Inai K, Foroutan A, Shams J, Naghizadeh MM, Hassan Z M. (2009b). Alterations in the serum levels of soluble L, P and E-selectin 20years after sulfur mustard exposure: Sardasht-Iran Cohort Study. Int Immunopharmacol. 9(13–14): 1477–1481.

Yaraee R, Hassan ZM, Pourfarzam S, Rezaei A, Faghihzadeh S, Ebtekar M, Soroush M-R, Ardestani SK, Kazemi H, Mahmoudi M. (2013). Fibrinogen and inflammatory cytokines in spontaneous sputum of sulfur-mustard-exposed civilians—Sardasht-Iran Cohort Study. Int Immunopharmacol 17(3): 968–973.

Zakerimoghadam M, Tavasoli K, Nejad AK, Khoshkesht S. (2011). The effect of breathing exercises on the fatigue levels of patients with chronic obstructive pulmonary disease. Acta Med Indones 43: 29–33.

Zandieh T, Marzban S, Tarabadi F, Ansari H. (1990). Defects of cell-mediated-immunity in mustard gas injury after years. Scand J Immunol 32(4): 423.

Interdisciplinary Toxicology

The Journal of Institute of Experimental Pharmacology of Slovak Academy of Sciences

Journal Information


CiteScore 2017: 2.36

SCImago Journal Rank (SJR) 2017: 0.580
Source Normalized Impact per Paper (SNIP) 2017: 1.134

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 396 385 31
PDF Downloads 144 141 9